Drug Profile


Alternative Names: BRN-0123183; DeOvo Lotion; HA-44; Ha44; Ha44 Gel; Xeglyze Lotion

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator Hatchtech
  • Class Antiparasitics; Heterocyclic compounds; Pyridines; Small molecules
  • Mechanism of Action Chelating agents; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pediculosis

Most Recent Events

  • 14 Sep 2015 Hatchteck enters into a deal with Dr Reddys Laboratories for commercialisation of abametapir in USA, Canada, India, Australia, New Zealand, Venezuala and countries of Common Independent States
  • 27 Jul 2015 No recent reports on development identified - Phase-II for Pediculosis (In adults) in Australia (Topical)
  • 27 Jul 2015 No recent reports on development identified - Phase-II for Pediculosis (In adolescents, In children, In adults) in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top